About Ligand Pharmaceuticals Incorporated
https://www.ligand.comLigand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide.
CEO
Todd C. Davis
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-11-02 | Forward | 1603:1000 |
| 2010-11-19 | Reverse | 1:6 |
ETFs Holding This Stock
IJR.AX
Weight:0.26%
Shares:1.17M
XUU.TO
Weight:0.01%
Shares:1.17M
VTS.AX
Weight:0.01%
Shares:584.59K
Summary
Showing Top 3 of 188
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
TUDOR INVESTMENT CORP ET AL
Shares:15.75M
Value:$3.1B
BLACKROCK, INC.
Shares:2.88M
Value:$566.92M
BLACKROCK INC.
Shares:2.87M
Value:$564.36M
Summary
Showing Top 3 of 418
About Ligand Pharmaceuticals Incorporated
https://www.ligand.comLigand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $115.46M ▲ | $35.71M ▼ | $117.27M ▲ | 101.57% ▲ | $5.99 ▲ | $149.23M ▲ |
| Q2-2025 | $47.63M ▲ | $36.28M ▼ | $4.85M ▲ | 10.18% ▲ | $0.25 ▲ | $20.9M ▲ |
| Q1-2025 | $45.33M ▲ | $76.7M ▲ | $-42.45M ▼ | -93.64% ▼ | $-2.21 ▼ | $-40.54M ▼ |
| Q4-2024 | $42.81M ▼ | $49.61M ▲ | $-31.09M ▼ | -72.62% ▼ | $-1.64 ▼ | $-29.69M ▼ |
| Q3-2024 | $51.81M | $36.17M | $-7.17M | -13.84% | $-0.39 | $3.4M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $664.52M ▲ | $1.48B ▲ | $526.6M ▲ | $950.17M ▲ |
| Q2-2025 | $255.3M ▲ | $948.6M ▲ | $120.08M ▲ | $828.53M ▲ |
| Q1-2025 | $208.9M ▼ | $905.43M ▼ | $109.9M ▼ | $795.53M ▼ |
| Q4-2024 | $256.17M ▲ | $941.77M ▼ | $111.33M ▼ | $830.44M ▼ |
| Q3-2024 | $219.64M | $954.87M | $113.69M | $841.18M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $117.27M ▲ | $13.16M ▼ | $-334.42M ▼ | $-10.25M ▼ | $-67.67M ▼ | $13.15M ▼ |
| Q2-2025 | $4.85M ▲ | $15.8M ▲ | $-10.67M ▼ | $15M ▲ | $19.68M ▲ | $15.58M ▲ |
| Q1-2025 | $-42.45M ▼ | $-25.52M ▼ | $4.89M ▲ | $-4.68M ▼ | $-24.32M ▼ | $-25.73M ▼ |
| Q4-2024 | $-31.09M ▼ | $28.47M ▼ | $-38.62M ▲ | $20.39M ▼ | $8.69M ▼ | $27.76M ▲ |
| Q3-2024 | $-7.17M | $36.53M | $-46.51M | $55.08M | $45.48M | $22.29M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Contract Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Evomela | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Financial Royalty Assets | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 Intangible Royalty Assets | $70.00M ▲ | $20.00M ▼ | $30.00M ▲ | $40.00M ▲ |
 Kyprolis | $0 ▲ | $0 ▲ | $10.00M ▲ | $10.00M ▲ |
 Material Sales Captisol | $20.00M ▲ | $10.00M ▼ | $10.00M ▲ | $10.00M ▲ |
 Royalty | $80.00M ▲ | $30.00M ▼ | $40.00M ▲ | $50.00M ▲ |
 Rylaze | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Teriparatide Injection | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Royalty Other | $10.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
CEO
Todd C. Davis
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-11-02 | Forward | 1603:1000 |
| 2010-11-19 | Reverse | 1:6 |
ETFs Holding This Stock
IJR.AX
Weight:0.26%
Shares:1.17M
XUU.TO
Weight:0.01%
Shares:1.17M
VTS.AX
Weight:0.01%
Shares:584.59K
Summary
Showing Top 3 of 188
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
TUDOR INVESTMENT CORP ET AL
Shares:15.75M
Value:$3.1B
BLACKROCK, INC.
Shares:2.88M
Value:$566.92M
BLACKROCK INC.
Shares:2.87M
Value:$564.36M
Summary
Showing Top 3 of 418